On June 22, Gelunhui reported that American biopharmaceutical company Gilead Sciences (GILD.US) rose more than 5% to $72.18 at one point during trading hours. The company announced that its research and development of "Lenacapavir" showed 100% effectiveness in preventing HIV. The latest published results come from a Phase III double-blind randomized study called "PURPOSE 1", which aims to evaluate the safety and effectiveness of Lenacapavir and Descovy in over 5,300 16-25 year old women across 25 sites in South Africa and 3 sites in Uganda. The results showed that there were 0 cases of HIV infection among the 2,134 women in the Lenacapavir group.
美股异动丨吉利德科学涨超5%，一款艾滋病预防药物取得惊人实验结果
Gilead Sciences rose more than 5% in the US stock market; a shocking experimental result was achieved for an AIDS prevention drug.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.